Turner was elected to serve Texas' 18th Congressional in November 2024. Turner was diagnosed with Osteosarcoma, a form of ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...

Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time Osteosarcoma (OS) is the most prevalent ...

Biosciences, announced that its collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an ...

OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2.

OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...

The company’s canine osteosarcoma program has identified potential biomarkers that may predict treatment response in humans. While the stock has experienced a significant decline of 62% year-to ...

Biosciences’ collaboration partner, PeriNess has entered into a Clinical Study Agreement to support an exploratory clinical ...

About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.